Medtronic Continues to Close Loop on Development of an Artificial Pancreas

by Ryan Harbison | 3Q 2016 | IN-4276

On September 28, 2016, Medtronic announced that it received approval from the U.S. Food and Drug Administration of its MiniMed 670G system, which is billed as the first hybrid closed-loop insulin delivery system. Medtronic had filed for premarket approval (PMA) of the system earlier this year, and an approval was not expected until early 2017 at the earliest. The speed with which the FDA granted approval is a result of the success of the system’s trial and the need for more efficient diabetes management systems. The device will be available for commercial use in spring 2017. At the American Diabetes Association’s Scientific Sessions in June 2016, Medtronic presented data from the six month trial of its MiniMed 670G diabetes management system. There were 124 patients who participated in the study. They used the device, which wirelessly connects an insulin pump and glucose monitor to automatically track and adjust blood glucose levels. The device is not a true closed-loop system because it still requires daily manual calibration and user input, but it is nonetheless a significant step in the development of a true closed-loop system—an artificial pancreas.

You must be a subscriber to view this Insight.

To find out more about subscribing:
Contact a representative about purchasing options.